Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Key Highlights
- ➤ARV-393 preliminary Phase 1 data will be presented at ASH December 14
- ➤ASH presentation covers safety, pharmacokinetics, and pharmacodynamics from all patients
- ➤Preliminary efficacy data will include patients with T-cell lymphomas
- ➤ARV-393 is being evaluated as monotherapy in relapsed/refractory NHL
- ➤ARV-393 is also being tested with glofitamab in chemotherapy-free DLBCL treatment
– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) –
NEW HAVEN, Conn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preliminary clinical data from the Phase 1 study of ARV-393 (zaloblideg) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented at the 2026 American Society of Hematology (ASH®) Annual Meeting, taking place December 12- 15, 2026, in New Orleans, Louisiana.
Get started
Create a free account to read the full story.